ARCA biopharma Establishes Special Committee of the Board of Directors
April 18 2022 - 4:30PM
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
applying a precision medicine approach to developing genetically
targeted therapies for cardiovascular diseases, today announced
that its Board of Directors has established a Special Committee to
evaluate strategic options for maximizing stockholder
value. The Company believes there are multiple
potential opportunities to enhance value for ARCA stockholders. The
Special Committee includes ARCA Board Chairman Robert E. Conway
(chair), and Board members Linda Grais, M.D. and Anders Hove, M.D.
About ARCA biopharmaARCA
biopharma is dedicated to developing genetically and other targeted
therapies for cardiovascular diseases through a precision medicine
approach to drug development. The U.S. FDA has granted the Gencaro
development program Fast Track designation and a Special Protocol
Assessment (SPA) agreement. At present, ARCA is engaged in
strategic planning, including for additional development of its
assets, collaborations and other strategic options. For more
information, please visit www.arcabio.com or follow the Company on
LinkedIn.
Safe Harbor StatementThis press
release contains "forward-looking statements" for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. These statements include, but are not limited to,
statements regarding potential strategic options (and the Company’s
exploration thereof), and potential future development plans for
Gencaro and rNAPc2, if any. Such statements are based on
management's current expectations and involve risks and
uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation, the
risks and uncertainties associated with: ARCA’s financial resources
and whether they will be sufficient to meet its business objectives
and operational requirements; the Company’s ability to complete a
strategic transaction, and the impact of competitive products and
technological changes. These and other factors are identified and
described in more detail in ARCA’s filings with the Securities and
Exchange Commission, including without limitation ARCA’s annual
report on Form 10-K for the year ended December 31, 2021,
and subsequent filings. ARCA disclaims any intent or obligation to
update these forward-looking statements.
Investor & Media Contact:
Derek Cole
720.940.2163
derek.cole@arcabio.com
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Jun 2024 to Jul 2024
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Jul 2023 to Jul 2024